BioXcellerator Joins Congressional Veterans Care Forum to Advance Dialogue on Evidence-Based Regenerative Medicine BioXcellerator, a global provider of evidence-based regenerative medicine therapies, has announced that its Co-Founder and Chief Executive Officer, Eric Stoffers, will participate in the upcoming Congressional Veterans…
Alkermes Reports Sustained Long-Term Benefits of Alixorexton in Narcolepsy Types 1 and 2 Alkermes plc has announced encouraging interim results from the ongoing long-term extension (LTE) study evaluating alixorexton, its investigational oral orexin 2 receptor (OX2R) agonist, in adults with…
PADCEV® Combination Approved for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Pfizer Inc. and Astellas Pharma Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv) in combination with the PD-1 inhibitor Keytruda® (pembrolizumab)…
OneLegacy Launches Western U.S.’s First Organ Procurement Organization-Based Ex Vivo Lung Perfusion Program to Expand Access to Lung Transplantation OneLegacy, the nonprofit organ procurement organization (OPO) serving Southern California, has announced the launch of the first in-house Ex Vivo Lung…
Auragens Named Stem Cell Treatment Center of the Year 2026, Earning Back-to-Back Recognition for Leadership in Regenerative Medicine Auragens has announced that it has been recognized as Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, marking…
Retham Technologies Launches Next-Generation Cryoplatelets to Improve Platelet Research and Laboratory Testing Retham Technologies, Inc. has announced the commercial launch of Retham Cryoplatelets™, a next-generation functional platelet product developed to address one of the most persistent challenges in biomedical research—the…
MEDIPOST Treats First U.S. Patient in Phase III Trial of Investigational Stem Cell Therapy for Knee Osteoarthritis MEDIPOST Inc., a biotechnology company specializing in the development of allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, has announced…
Leo Cancer Care Secures $65 Million Series D Funding to Expand Upright Cancer Imaging and Treatment Platform Leo Cancer Care has announced the successful completion of an oversubscribed $65 million Series D financing round, providing the company with significant new…
Agenus Reports Three-Year Phase 1b Results for Botensilimab Plus Balstilimab Showing Durable Survival in Refractory MSS Metastatic Colorectal Cancer Agenus Inc., a biotechnology company focused on advancing next-generation immuno-oncology therapies, has announced encouraging three-year follow-up results from its fully enrolled…
bioAffinity Technologies Reports More Than 200% Growth in CyPath® Lung Sales as Physician Adoption Continues to Accelerate bioAffinity Technologies, Inc., a biotechnology company dedicated to developing innovative, noninvasive diagnostic solutions for lung cancer and other pulmonary diseases, has announced strong…
Orion and Shilpa Medicare Expand European Nivolumab Biosimilar Partnership Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and long-term supply agreement with Orion Corporation for the development and commercialization…
Elucid to Showcase Next-Generation AI-Powered Coronary CT Technologies and Advance Its CCTA 3.0 Vision at SCCT 2026 Elucid, a medical technology company specializing in artificial intelligence-powered coronary CT angiography (CCTA) analysis, has announced its largest and most comprehensive participation to…